Lakshmi Sukumaran1, Natalie L McCarthy2, Elyse O Kharbanda3, Gabriela Vazquez-Benitez3, Heather S Lipkind4, Lisa Jackson5, Nicola P Klein6, Allison L Naleway7, David L McClure8, Rulin C Hechter9, Alison T Kawai10, Jason M Glanz11, Eric S Weintraub2. 1. Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia; lsukumaran@cdc.gov. 2. Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia. 3. HealthPartners Institute, Minneapolis, Minnesota. 4. Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, Yale University, New Haven, Connecticut. 5. Kaiser Permanente Washington Health Research Institute, Seattle, Washington. 6. Division of Research, Kaiser Permanente of Northern California, Oakland, California. 7. Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon. 8. Marshfield Clinic Research Institute, Marshfield, Wisconsin. 9. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California. 10. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts; and. 11. Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado.
Abstract
BACKGROUND: The Advisory Committee on Immunization Practices currently recommends pregnant women receive influenza and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines. There are limited studies of the long-term safety in infants for vaccines administered during pregnancy. We evaluate whether maternal receipt of influenza and Tdap vaccines increases the risk of infant hospitalization or death in the first 6 months of life. METHODS: We included singleton, live birth pregnancies in the Vaccine Safety Datalink between 2004 and 2014. Outcomes were infant hospitalizations and mortality in the first 6 months of life. We performed a case-control study matching case patients and controls 1:1 and used conditional logistic regression to estimate odds ratios for maternal exposure to influenza and/or Tdap vaccines in pregnancy. RESULTS: There were 413 034 live births in our population. Of these, 25 222 infants had hospitalizations and 157 infants died in the first 6 months of life. We found no association between infant hospitalization and maternal influenza (adjusted odds ratio: 1.00; 95% confidence interval [CI]: 0.96-1.04) or Tdap (adjusted odds ratio: 0.94; 95% CI: 0.88-1.01) vaccinations. We found no association between infant mortality and maternal influenza (adjusted odds ratio: 0.96; 95% CI: 0.54-1.69) or Tdap (adjusted odds ratio: 0.44; 95% CI: 0.17-1.13) vaccinations. CONCLUSIONS: We found no association between vaccination during pregnancy and risk of infant hospitalization or death in the first 6 months of life. These findings support the safety of current recommendations for influenza and Tdap vaccination during pregnancy.
BACKGROUND: The Advisory Committee on Immunization Practices currently recommends pregnant women receive influenza and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines. There are limited studies of the long-term safety in infants for vaccines administered during pregnancy. We evaluate whether maternal receipt of influenza and Tdap vaccines increases the risk of infant hospitalization or death in the first 6 months of life. METHODS: We included singleton, live birth pregnancies in the Vaccine Safety Datalink between 2004 and 2014. Outcomes were infant hospitalizations and mortality in the first 6 months of life. We performed a case-control study matching case patients and controls 1:1 and used conditional logistic regression to estimate odds ratios for maternal exposure to influenza and/or Tdap vaccines in pregnancy. RESULTS: There were 413 034 live births in our population. Of these, 25 222 infants had hospitalizations and 157 infants died in the first 6 months of life. We found no association between infant hospitalization and maternal influenza (adjusted odds ratio: 1.00; 95% confidence interval [CI]: 0.96-1.04) or Tdap (adjusted odds ratio: 0.94; 95% CI: 0.88-1.01) vaccinations. We found no association between infant mortality and maternal influenza (adjusted odds ratio: 0.96; 95% CI: 0.54-1.69) or Tdap (adjusted odds ratio: 0.44; 95% CI: 0.17-1.13) vaccinations. CONCLUSIONS: We found no association between vaccination during pregnancy and risk of infant hospitalization or death in the first 6 months of life. These findings support the safety of current recommendations for influenza and Tdap vaccination during pregnancy.
Authors: Petra Zimmermann; Kirsten P Perrett; Nicole L Messina; Susan Donath; Nicole Ritz; Fiona R M van der Klis; Nigel Curtis Journal: EClinicalMedicine Date: 2019-07-26
Authors: Helen Petousis-Harris; Yannan Jiang; Lennex Yu; Donna Watson; Tony Walls; Nikki Turner; Anna S Howe; Jennifer B Griffin Journal: Vaccines (Basel) Date: 2019-10-11
Authors: Dayna R Clark; Saad B Omer; Milagritos D Tapia; Marta C Nunes; Clare L Cutland; James M Tielsch; Niteen Wairagkar; Shabir A Madhi Journal: Pediatr Infect Dis J Date: 2020-07 Impact factor: 2.129